Chembio Diagnostics Inc (CEMI)

[surf1944]

8:53AM Chembio Diagnostics: Positive data from independent study of chembio diagnostics' rapid, point-of-care syphilis test published in clinical infectious diseases (CEMI) 4.50 : Co reported that data from a study evaluating performance characteristics (sensitivity and specificity) of the Co's patented Dual Path Platform (DPP) rapid point-of-care test for syphilis was recently published online in Clinical Infectious Diseases and is expected to be published in the upcoming print edition. DPP Syphilis Screen and Confirm is the first dual non-treponemal (screen for infection) and treponemal (confirms an active syphilis infection if non-treponemal is reactive) POC syphilis test that permits the simultaneous yet separate detection of both markers at the POC. The study authors concluded that DPP Syphilis Screen and Confirm demonstrated good sensitivity and specificity in detecting treponemal and non-treponemal antibodies in three kinds of blood specimens.